Publikationen GEPNET-KUM

Impact of sex hormones on pheochromocytomas, paragangliomas and gastro-enteropancreatic neuroendocrine tumors. Nölting, Wang, Auernhammer, et al. Eur J Endocrinol. Accepted for publication Nov.2024
ESR Essentials: role of PET/CT in neuroendocrine tumors-practice recommendations by the European Society for Hybrid, Molecular and Translational Imaging. Ebner R, Sheikh GT, Brendel M, Ricke J, Cyran CC. Eur Radiol. 2024 Oct 10. doi: 10.1007/s00330-024-11095-7. Online ahead of print. PMID: 39387873
Peptide-guided adaptor-CAR T-Cell therapy for the treatment of SSTR2-expressing neuroendocrine tumors. Pellegrino C, Favalli N, Volta L, Benz R, Puglioli S, Bassi G, Zitzmann K, Auernhammer CJ, Nölting S, Magnani CF, Neri D, Beuschlein F, Manz MG. Oncoimmunology. 2024 Oct 3;13(1):2412371. doi: 10.1080/2162402X.2024.2412371. eCollection 2024. PMID: 39376579
Quantitative SSTR-PET/CT: a potential tool for predicting everolimus response in neuroendoctine tumour patients. Karim H, Winkelmann M, Grawe F, Völter F, Auernhammer C, Rübenthaler J, Ricke J, Ingenerf M, Schmid-Tannwald C. Radiol Oncol. 2024 Jun 12;58(3):348-356. doi: 10.2478/raon-2024-0032. PMID: 38861687
Synchronous neuroendocine liver metastases in comparison to primary pancreatic neuroendocrine tumors on MRI and SSR-PET/CT. Horng A, Ingenerf M, Berger F, Steffinger D, Rübenthaler J, Zacherl M, Wenter V, Ricke J, Schmid-Tannwald C. Front Oncol. 2024 May 31;14:1352538. doi: 10.3389/fonc.2024.1352538. PMID: 38884077
[Imaging of pancreatic neuroendocrine tumors]. Berger F, Ingenerf M, Auernhammer CJ, Cyran C, Ebner R, Zacherl M, Ricke J, Schmid-Tannwald C. Radiologie (Heidelb). 2024 May 24. doi: 10.1007/s00117-024-01316-x. Online ahead of print. PMID: 38789854 Review. German.
Validation of the standardization framework SSTR-RADS 1.0 for neuroendocrine tumors using the novel SSTR-targeting peptide [(18)F]SiTATE. Ebner R, Lohse A, Fabritius MP, Rübenthaler J, Wängler C, Wängler B, Schirrmacher R, Völter F, Schmid HP, Unterrainer LM, Öcal O, Hinterberger A, Spitzweg C, Auernhammer CJ, Geyer T, Ricke J, Bartenstein P, Holzgreve A, Grawe F. Eur Radiol. 2024 May 20. doi: 10.1007/s00330-024-10788-3. Online ahead of print. PMID: 38769164
[Imaging of neuroendocrine tumors of the gastrointestinal tract : Value of (hybrid) imaging diagnostics in radiology]. Ebner R, Rübenthaler J, Ricke J, Sheikh GT, Unterrainer LM, Auernhammer CJ, Spitzweg C, Brendel M, Schmid-Tannwald C, Cyran CC. Radiologie (Heidelb). 2024 May 7. doi: 10.1007/s00117-024-01296-y. Online ahead of print. PMID: 38713221 Review. German.
[Current WHO classification (2022) of neuroendocrine neoplasms]. Buchstab O, Knösel T. Radiologie (Heidelb). 2024 Apr 15. doi: 10.1007/s00117-024-01295-z. Online ahead of print. PMID: 38622292 Review. German.
Utility of clinical and MR imaging parameters for prediction and monitoring of response to capecitabine and temozolomide (CAPTEM) therapy in patients with liver metastases of neuroendocrine tumors. Ingenerf M, Auernhammer C, Lorbeer R, Winkelmann M, Mansournia S, Mansour N, Hesse N, Heinrich K, Ricke J, Berger F, Schmid-Tannwald C. Radiol Oncol. 2024 Apr 14. doi: 10.2478/raon-2024-0024. Online ahead of print. PMID: 38613843
Opposing effects of cannabidiol in patient-derived neuroendocrine tumor, pheochromocytoma/paraganglioma primary cultures. Wang K, Schober L, Fischer A, Bechmann N, Maurer J, Peischer L, Reul A, Hantel C, Reincke M, Beuschlein F, Robledo M, Mohr H, Pellegata NS, Schilbach K, Knösel T, Ilmer M, Angele M, Kroiss M, Maccio U, Broglie-Däppen M, Vetter D, Lehmann K, Pacak K, Grossman AB, Auernhammer CJ, Zitzmann K, Nölting S. J Clin Endocrinol Metab. 2024 Apr 12:dgae241. doi: 10.1210/clinem/dgae241. Online ahead of print. PMID: 38605427
Concomitant inhibition of PI3K/mTOR signaling pathways boosts antiproliferative effects of lanreotide in bronchopulmonary neuroendocrine tumor cells. von Hessert-Vaudoncourt C, Lelek S, Geisler C, Hartung T, Bröker V, Briest F, Mochmann L, Jost-Brinkmann F, Sedding D, Benecke J, Freitag H, Wolfshöfer S, Lammert H, Nölting S, Hummel M, Schrader J, Grabowski P. Front Pharmacol. 2024 Feb 5;15:1308686. doi: 10.3389/fphar.2024.1308686. eCollection 2024. PMID: 38375032
Improving susceptibility of neuroendocrine tumors to radionuclide therapies: personalized approaches towards complementary treatments. Richter S, Steenblock C, Fischer A, Lemm S, Ziegler CG, Bechmann N, Nölting S, Pietzsch J, Ullrich M. Theranostics. 2024 Jan 1;14(1):17-32. doi: 10.7150/thno.87345. eCollection 2024. PMID: 38164150
Neuroendocrine liver metastases treated using transarterial radioembolization: Identification of prognostic parameters at 68Ga-DOTATATE PET/CT. Ingenerf M, Grawe F, Winkelmann M, Karim H, Ruebenthaler J, Fabritius MP, Ricke J, Seidensticker R, Auernhammer CJ, Zacherl MJ, Seidensticker M, Schmid-Tannwald C. Diagn Interv Imaging. 2024 Jan;105(1):15-25. doi: 10.1016/j.diii.2023.06.007. Epub 2023 Jul 13. PMID: 37453859

Impact of the PI3K-alpha inhibitor alpelisib on everolimus resistance and somatostatin receptor expression in an orthotopic pancreatic NEC xenograft mouse model. Mohan AM, Prasad S, Schmitz-Peiffer F, Lange C, Lukas M, Koziolek EJ, Albrecht J, Messroghli D, Stein U, Ilmer M, Wang K, Schober L, Reul A, Maurer J, Friemel J, Weber A, Zuellig RA, Hantel C, Fritsch R, Reincke M, Pacak K, Grossman AB, Auernhammer CJ, Beuschlein F, Brenner W, Beindorff N, Nölting S. Endocr Relat Cancer. 2023 Nov 30;31(1):e230041. doi: 10.1530/ERC-23-0041. Print 2024 Jan 1. PMID: 37943630
Quantitative SSTR-PET/CT for predicting response and survival outcomes in patients with pancreatic neuroendocrine tumors receiving CAPTEM. Ingenerf M, Karim H, Auernhammer C, Zacherl M, Wenter V, Winkelmann M, Ricke J, Berger F, Schmid-Tannwald C. Radiol Oncol. 2023 Nov 30;57(4):436-445. doi: 10.2478/raon-2023-0055. eCollection 2023 Dec 1. PMID: 38038419
Artificial Intelligence in Oncological Hybrid Imaging. Feuerecker B, Heimer MM, Geyer T, Fabritius MP, Gu S, Schachtner B, Beyer L, Ricke J, Gatidis S, Ingrisch M, Cyran CC. Nuklearmedizin. 2023 Oct;62(5):296-305. doi: 10.1055/a-2157-6810. Epub 2023 Oct 6. PMID: 37802057 Review. English.
Diagnostic accuracy of SSR-PET/CT compared to histopathology in the identification of liver metastases from well-differentiated neuroendocrine tumors. Fabritius MP, Soltani V, Cyran CC, Ricke J, Bartenstein P, Auernhammer CJ, Spitzweg C, Schnitzer ML, Ebner R, Mansournia S, Hinterberger A, Lohse A, Sheikh GT, Winkelmann M, Knösel T, Ingenerf M, Schmid-Tannwald C, Kunz WG, Rübenthaler J, Grawe F. Cancer Imaging. 2023 Sep 28;23(1):92. doi: 10.1186/s40644-023-00614-2. PMID: 37770958
Evaluation of MRI in the diagnostic accuracy of extrahepatic metastases in neuroendocrine tumors in comparison with the reference standard somatostatin-receptor-PET/CT. Ingenerf M, Rübenthaler J, Wenter V, Zacherl M, Völter F, Winkelmann M, Karim H, Schinner R, Ricke J, Berger F, Schmid-Tannwald C. Front Oncol. 2023 Aug 15;13:1194152. doi: 10.3389/fonc.2023.1194152. eCollection 2023. PMID: 37655102
68 Ga-DOTATOC PET/CT in Pancreatic Metastasis From Clear Cell Renal Cell Carcinoma. Mansour N, Rangan K, Tiling R, Rübenthaler J, Fabritius MP. Clin Nucl Med. 2023 Aug 1;48(8):712-713. doi: 10.1097/RLU.0000000000004730. Epub 2023 Jun 6. PMID: 37276508
Endoscopic and Surgical Management of Non-Metastatic Ampullary Neuroendocrine Neoplasia: A Multi-Institutional Pancreas2000/EPC Study. Karam E, Hollenbach M, Abou Ali E, Auriemma F, Anderloni A, Barbier L, Belfiori G, Caillol F, Crippa S, Del Chiaro M, De Ponthaud C, Dahel Y, Falconi M, Giovannini M, Heling D, Inoue Y, Jarnagin WR, Leung G, Lupinacci RM, Mariani A, Masaryk V, Miksch RC, Musquer N, Napoleon B, Oba A, Partelli S, Petrone MC, Prat F, Repici A, Sauvanet A, Salzmann K, Schattner MA, Schulick R, Schwarz L, Soares K, Souche FR, Truant S, Vaillant JC, Wang T, Wedi E, Werner J, Weismüller TJ, Wichmann D, Will U, Zaccari P, Gulla A, Heise C, Regner S, Gaujoux S; Pancreas 2000 Research Group. Neuroendocrinology. 2023;113(10):1024-1034. doi: 10.1159/000531712. Epub 2023 Jun 27. PMID: 37369186
18F-Labeled Somatostatin Analogs as PET Tracers for the Somatostatin Receptor: Ready for Clinical Use. Leupe H, Ahenkorah S, Dekervel J, Unterrainer M, Van Cutsem E, Verslype C, Cleeren F, Deroose CM. J Nucl Med. 2023 May 11:265622. doi: 10.2967/jnumed.123.265622. Online ahead of print. PMID: 37169533
Diagnostic performance of PET/CT in the detection of liver metastases in well-differentiated NETs. Grawe F, Rosenberger N, Ingenerf M, Beyer L, Eschbach R, Todica A, Seidensticker R, Schmid-Tannwald C, Cyran CC, Ricke J, Bartenstein P, Auernhammer CJ, Ruebenthaler J, Fabritius MP. Cancer Imaging. 2023 Apr 25;23(1):41. doi: 10.1186/s40644-023-00556-9. PMID: 37098632
Validation of the SSTR-RADS 1.0 for the structured interpretation of SSTR-PET/CT and treatment planning in neuroendocrine tumor (NET) patients. Grawe F, Ebner R, Geyer T, Beyer L, Winkelmann M, Sheikh GT, Eschbach R, Schmid-Tannwald C, Cyran CC, Ricke J, Bartenstein P, Heimer MM, Faggioni L, Spitzweg C, Fabritius MP, Auernhammer CJ, Ruebenthaler J. Eur Radiol. 2023 Mar 25. doi: 10.1007/s00330-023-09518-y. Epub ahead of print. PMID: 36964768
The other colon cancer: a population-based cohort study of appendix tumour trends and prognosis. Halfter K, Schubert-Fritschle G, Klauschen F, Werner J, Mayerle J, Weichert W, Friess H, Schmid R, Kremer M, Ruppert R, Hoelzl J, Krenz D, Nerlich A, Agha A, Fuchs M, Becker I, Nowak K, Engel J, Schlesinger-Raab A. Colorectal Dis. 2023 Feb 7. doi: 10.1111/codi.16510. Epub ahead of print. PMID: 36748436
Comparison of somatostatin receptor expression in patients with neuroendocrine tumours with and without somatostatin analogue treatment imaged with [18F]SiTATE. Eschbach RS, Hofmann M, Späth L, Sheikh GT, Delker A, Lindner S, Jurkschat K, Wängler C, Wängler B, Schirrmacher R, Tiling R, Brendel M, Wenter V, Dekorsy FJ, Zacherl MJ, Todica A, Ilhan H, Grawe F, Cyran CC, Unterrainer M, Rübenthaler J, Knösel T, Paul T, Boeck S, Westphalen CB, Spitzweg C, Auernhammer CJ, Bartenstein P, Unterrainer LM, Beyer L. Front Oncol. 2023 Jan 30;13:992316. doi: 10.3389/fonc.2023.992316. PMID: 36793617

Evaluation of the Efficacy of a Combined Treatment Using the mTOR-Inhibitor Everolimus and [177Lu]Lu-DOTA-TATE in Nude CD1 Mice with SSTR-Expressing Pancreatic AR42J Xenograft Tumors. Zellmer J, Yen HY, Kaiser L, Gildehaus FJ, Böning G, Steiger K, Hacker M, Bartenstein P, Todica A, Haug AR, Ilhan H. Biomedicines. 2022 Dec 1;10(12):3102. doi: 10.3390/biomedicines10123102. PMID: 36551858
Heterotopic Transcatheter Tricuspid Valve Replacement in a Patient With Carcinoid Heart Disease. Stolz L, Doldi PM, Weckbach LT, Schwinger RHG, Stocker TJ, Massberg S, Näbauer M, Hausleiter J. JACC Case Rep. 2022 Nov 16;4(23):101679. doi: 10.1016/j.jaccas.2022.10.011. eCollection 2022 Dec 7. PMID: 36438434
Treatment Assessment of pNET and NELM after Everolimus by Quantitative MRI Parameters. Ingenerf M, Kiesl S, Winkelmann M, Auernhammer CJ, Rübenthaler J, Grawe F, Fabritius MP, Ricke J, Schmid-Tannwald C. Biomedicines. 2022 Oct 18;10(10):2618. doi: 10.3390/biomedicines10102618. PMID: 36289880
Management of asymptomatic sporadic non-functioning pancreatic neuroendocrine neoplasms no larger than 2 cm: interim analysis of prospective ASPEN trial. Partelli S, Massironi S, Zerbi A, Niccoli P, Kwon W, Landoni L, Panzuto F, Tomazic A, Bongiovanni A, Kaltsas G, Sauvanet A, Bertani E, Mazzaferro V, Caplin M, Armstrong T, Weickert MO, Ramage J, Segelov E, Butturini G, Staettner S, Cives M, Frilling A, Moulton CA, He J, Boesch F, Selberheer A, Twito O, Castaldi A, De Angelis CG, Gaujoux S, Holzer K, Wilson CH, Almeamar H, Vigia E, Muffatti F, Lucà M, Lania A, Ewald J, Kim H, Salvia R, Rinzivillo M, Smid A, Gardini A, Tsoli M, Hentic O, Colombo S, Citterio D, Toumpanakis C, Ramsey E, Randeva HS, Srirajaskanthan R, Croagh D, Regi P, Gasteiger S, Invernizzi P, Ridolfi C, Giovannini M, Jang JY, Bassi C, Falconi M. Br J Surg. 2022 Aug 20:znac267. doi: 10.1093/bjs/znac267. Online ahead of print. PMID: 35986682
Apparent diffusion coefficients (ADC) in response assessment of transarterial radioembolization (TARE) for liver metastases of neuroendocrine tumors (NET): a feasibility study. Katharina Ingenerf M, Karim H, Fink N, Ilhan H, Ricke J, Treitl KM, Schmid-Tannwald C. Acta Radiol. 2022 Jul;63(7):877-888. doi: 10.1177/02841851211024004. Epub 2021 Jul 5. PMID: 34225464
Immuno-histochemical correlation of fibrosis-related markers with the desmoplastic reaction of the mesentery in small intestine neuroendocrineneoplasms. Bösch F, Altendorf-Hofmann A, Koliogiannis V, Ilhan H, Jacob S, Pretzsch E, Nölting S, Werner J, Klauschen F, Auernhammer CJ, Angele MK, Knösel T. J Cancer Res Clin Oncol. 2022 Jul 7. doi: 10.1007/s00432-022-04119-6. Online ahead of print. PMID: 35796776
Immuntherapie bei neuroendokrinen Tumoren. Auernhammer, C.J., Pavel, M.E. Onkologie 28, 660–666 (2022). https://doi.org/10.1007/s00761-022-01199-4
Impact of tumor size and location on endoscopic ultrasound-guided sampling of pancreatic neuroendocrine tumors: A recursive partitioning analysis. Sirtl S, Mahajan UM, Auernhammer CJ, Dziadkiewicz P, Hohmann E, Wójcik M, Kos-Kudła B, Hartleb M, Knösel T, Schirra J, Mayerle J, Schulz C, Żorniak M. Pancreatology. 2022 Jun;22(5):644-650. doi: 10.1016/j.pan.2022.04.014. Epub 2022 May 12. PMID: 35589512

Development of severe intrapulmonary shunting in a patient with carcinoid heart disease after closure of a persistent foramen ovale: a case report. Schüttler D, Mourouzis K, Auernhammer CJ, Rizas KD. Eur Heart J Case Rep. 2021 Dec 4;5(12):ytab494. doi: 10.1093/ehjcr/ytab494. PMID: 35047738
Dosimetry and optimal scan time of [18F]SiTATE-PET/CT in patients with neuroendocrine tumours. Beyer L, Gosewisch A, Lindner S, Völter F, Mittlmeier LM, Tiling R, Brendel M, Cyran CC, Unterrainer M, Rübenthaler J, Auernhammer CJ, Spitzweg C, Böning G, Gildehaus FJ, Jurkschat K, Wängler C, Wängler B, Schirrmacher R, Wenter V, Todica A, Bartenstein P, Ilhan H. Eur J Nucl Med Mol Imaging. 2021 Oct;48(11):3571-3581. doi: 10.1007/s00259-021-05351-x. Epub 2021 Apr 29. PMID: 33928401
Treatment of advanced gastroenteropancreatic neuroendocrine neoplasia, are we on the way to personalised medicine? Rinke A, Auernhammer CJ, Bodei L, Kidd M, Krug S, Lawlor R, Marinoni I, Perren A, Scarpa A, Sorbye H, Pavel ME, Weber MM, Modlin I, Gress TM. Gut. 2021 Sep;70(9):1768-1781. doi: 10.1136/gutjnl-2020-321300. Epub 2021 Mar 10. PMID: 33692095
68Ga-DOTATATE PET/CT and MRI with Diffusion-Weighted Imaging (DWI) in Short- and Long-Term Assessment of Tumor Response of Neuroendocrine Liver Metastases (NELM) Following Transarterial Radioembolization (TARE). Ingenerf M, Kiesl S, Karim S, Beyer L, Ilhan H, Rübenthaler J, Seidensticker M, Ricke J, Schmid-Tannwald C. Cancers (Basel). 2021 Aug 27;13(17):4321. doi: 10.3390/cancers13174321. PMID: 34503131
Feasibility and Early Clinical Experience of Online Adaptive MR-Guided Radiotherapy of Liver Tumors. Rogowski P, von Bestenbostel R, Walter F, Straub K, Nierer L, Kurz C, Landry G, Reiner M, Auernhammer CJ, Belka C, Niyazi M, Corradini S. Cancers (Basel). 2021 Mar 26;13(7):1523. doi: 10.3390/cancers13071523. PMID: 33810244
Antitumoral Activity of the MEK Inhibitor Trametinib (TMT212) Alone and in Combination with the CDK4/6 Inhibitor Ribociclib (LEE011) in Neuroendocrine Tumor Cells In Vitro. Jin XF, Spöttl G, Maurer J, Nölting S, Auernhammer CJ. Cancers (Basel). 2021 Mar 23;13(6):1485. doi: 10.3390/cancers13061485. PMID: 33807122
Cost-Effectiveness Analysis of 68Ga DOTA-TATE PET/CT, 111In-Pentetreotide SPECT/CT and CT for Diagnostic Workup of Neuroendocrine Tumors. Froelich MF, Schnitzer ML, Holzgreve A, Gassert FG, Gresser E, Overhoff D, Schwarze V, Fabritius MP, Nörenberg D, von Münchhausen N, Hokamp NG, Auernhammer CJ, Ilhan H, Todica A, Rübenthaler J. Diagnostics (Basel). 2021 Feb 18;11(2):334. doi: 10.3390/diagnostics11020334. PMID: 33670457
Mixed large cell neuroendocrine carcinoma and squamous cell carcinoma of the colon: detailed molecular characterisation of two cases indicates a distinct colorectal cancer entity. Woischke C, Jung P, Jung A, Kumbrink J, Eisenlohr S, Auernhammer CJ, Vieth M, Kirchner T, Neumann J. J Pathol Clin Res. 2021 Jan;7(1):75-85. doi: 10.1002/cjp2.183. Epub 2020 Nov 16. PMID: 33197299

Management of Asymptomatic Sporadic Nonfunctioning Pancreatic Neuroendocrine Neoplasms (ASPEN) ≤2 cm: Study Protocol for a Prospective Observational Study. Partelli S, Ramage JK, Massironi S, Zerbi A, Kim HB, Niccoli P, Panzuto F, Landoni L, Tomazic A, Ibrahim T, Kaltsas G, Bertani E, Sauvanet A, Segelov E, Caplin M, Coppa J, Armstrong T, Weickert MO, Butturini G, Staettner S, Boesch F, Cives M, Moulton CA, He J, Selberherr A, Twito O, Castaldi A, De Angelis CG, Gaujoux S, Almeamar H, Frilling A, Vigia E, Wilson C, Muffatti F, Srirajaskanthan R, Invernizzi P, Lania A, Kwon W, Ewald J, Rinzivillo M, Nessi C, Smid LM, Gardini A, Tsoli M, Picardi EE, Hentic O, Croagh D, Toumpanakis C, Citterio D, Ramsey E, Mosterman B, Regi P, Gasteiger S, Rossi RE, Smiroldo V, Jang JY, Falconi M. Front Med (Lausanne). 2020 Dec 23;7:598438. doi: 10.3389/fmed.2020.598438. PMID: 33425946
Radiosynthesis of [18F]SiFAlin-TATE for clinical neuroendocrine tumor positron emission tomography. Lindner S, Wängler C, Bailey JJ, Jurkschat K, Bartenstein P, Wängler B, Schirrmacher R. Nat Protoc. 2020 Dec;15(12):3827-3843. doi: 10.1038/s41596-020-00407-y. Epub 2020 Nov 23. PMID: 33230332
Distinct Expression Patterns of VEGFR 1-3 in Gastroenteropancreatic Neuroendocrine Neoplasms: Supporting Clinical Relevance, but not a Prognostic Factor. Bösch F, Altendorf-Hofmann A, Jacob S, Auernhammer CJ, Spitzweg C, Boeck S, Schubert-Fritschle G, Werner J, Kirchner T, Angele MK, Knösel T. J Clin Med. 2020 Oct 21;9(10):3368. doi: 10.3390/jcm9103368. PMID: 33096620
Automated production of [18F]SiTATE on a Scintomics GRP™ platform for PET/CT imaging of neuroendocrine tumors. Lindner S, Simmet M, Gildehaus FJ, Jurkschat K, Wängler C, Wängler B, Bartenstein P, Schirrmacher R, Ilhan H. Nucl Med Biol. 2020 Sep-Oct;88-89:86-95. doi: 10.1016/j.nucmedbio.2020.07.008. Epub 2020 Jul 30. PMID: 32828007
Operationsindikationen bei neuroendokrinen Neoplasien des Pankreas [Indications for the Surgical Management of Pancreatic Neuroendocrine Neoplasms]. Bösch F, Belyaev O, Brunner M, Müller-Debus CF; Olga Radulova-Mauersberger; Grützmann R, Keck T, Uhl W, Witzigmann H, Werner J. Zentralbl Chir. 2020 Aug;145(4):365-373. German. doi: 10.1055/a-1168-7103. Epub 2020 Jun 29. PMID: 32599635
Radioembolization for neuroendocrine liver metastases is safe and effective prior to major hepatic resection. Bösch F, Ilhan H, Pfahler V, Thomas M, Knösel T, Eibl V, Pratschke S, Bartenstein P, Seidensticker M, Auernhammer CJ, Spitzweg C, Guba MO, Werner J, Angele MK. Hepatobiliary Surg Nutr. 2020 Jun;9(3):312-321. doi: 10.21037/hbsn.2019.07.11. PMID: 32509817
Toxicity of a combined therapy using the mTOR-inhibitor everolimus and PRRT with [177Lu]Lu-DOTA-TATE in Lewis rats. Zellmer J, Yen HY, Kaiser L, Mille E, Gildehaus FJ, Böning G, Steiger K, Hacker M, Bartenstein P, Todica A, Haug AR, Ilhan H. EJNMMI Res. 2020 Apr 25;10(1):41. doi: 10.1186/s13550-020-00628-y. PMID: 32335736
Biodistribution and first clinical results of 18F-SiFAlin-TATE PET: a novel 18F-labeled somatostatin analog for imaging of neuroendocrine tumors. Ilhan H, Lindner S, Todica A, Cyran CC, Tiling R, Auernhammer CJ, Spitzweg C, Boeck S, Unterrainer M, Gildehaus FJ, Böning G, Jurkschat K, Wängler C, Wängler B, Schirrmacher R, Bartenstein P. Eur J Nucl Med Mol Imaging. 2020 Apr;47(4):870-880. doi: 10.1007/s00259-019-04501-6. Epub 2019 Sep 6. PMID: 31492994
Inhibition of Wnt/β-Catenin Signaling in Neuroendocrine Tumors in vitro: Antitumoral Effects. Jin XF, Spoettl G, Maurer J, Nölting S, Auernhammer CJ. Cancers (Basel). 2020 Feb 4;12(2):345. doi: 10.3390/cancers12020345. PMID: 32033025

Indications for resection and perioperative outcomes of surgery for pancreatic neuroendocrine neoplasms in Germany: an analysis of the prospective DGAV StuDoQ|Pancreas registry. Mintziras I, Keck T, Werner J, Fichtner-Feigl S, Wittel U, Senninger N, Vowinkel T, Köninger J, Anthuber M, Geißler B, Bartsch DK; StuDoQ|Pancreas Study Group of the German Society for General, Visceral Surgery (DGAV). Surg Today. 2019 Dec;49(12):1013-1021. doi: 10.1007/s00595-019-01838-1. Epub 2019 Jun 25. PMID: 31240463
Karzinoide der Lunge und im Abdomen [Pulmonary carcinoids and carcinoids of the small intestine]. Winter KS, Auernhammer CJ, Todica A, Ricke J, Cyran C. Radiologe. 2019 Nov;59(11):968-974. German. doi: 10.1007/s00117-019-00597-x. PMID: 31570965
Neuroendokrine Tumoren von Magen, Duodenum und Pankreas : Stellenwert der (hybriden) radiologischen Diagnostik [Neuroendocrine tumors of the stomach, duodenum and pancreas : Value of (hybrid) radiological diagnostics]. Rübenthaler J, Auernhammer C, Harun I, Ricke J, Cyran CC. Radiologe. 2019 Nov;59(11):961-967. German. doi: 10.1007/s00117-019-00593-1. PMID: 31515568
Neues zur Therapie von neuroendokrinen Tumoren des gastroenteropankreatischen Systems [Current standards and novel developments in the treatment of neuroendocrine tumors of the gastroenteropancreatic system]. Auernhammer CJ, Spitzweg C, Böck S, Knösel T, Bartenstein P. Dtsch Med Wochenschr. 2019 Oct;144(20):1390-1395. German. doi: 10.1055/a-0801-3686. Epub 2019 Oct 8. PMID: 31594011
Combination of 5-Fluorouracil with Epigenetic Modifiers Induces Radiosensitization, Somatostatin Receptor 2 Expression, and Radioligand Binding in Neuroendocrine Tumor Cells In Vitro. Jin XF, Auernhammer CJ, Ilhan H, Lindner S, Nölting S, Maurer J, Spöttl G, Orth M. J Nucl Med. 2019 Sep;60(9):1240-1246. doi: 10.2967/jnumed.118.224048. Epub 2019 Feb 22. PMID: 30796167
Salvage PRRT with 177Lu-DOTA-octreotate in extensively pretreated patients with metastatic neuroendocrine tumor (NET): dosimetry, toxicity, efficacy, and survival. Rudisile S, Gosewisch A, Wenter V, Unterrainer M, Böning G, Gildehaus FJ, Fendler WP, Auernhammer CJ, Spitzweg C, Bartenstein P, Todica A, Ilhan H. BMC Cancer. 2019 Aug 8;19(1):788. doi: 10.1186/s12885-019-6000-y. PMID: 31395036
Treatment with somatostatin analogs induces differentially expressed let-7c-5p and mir-3137 in small intestine neuroendocrine tumors. Bösch F, Bazhin AV, Heublein S, Brüwer K, Knösel T, Reiter FP, Auernhammer CJ, Guba MO, Spitzweg C, Werner J, Angele MK. BMC Cancer. 2019 Jun 13;19(1):575. doi: 10.1186/s12885-019-5794-y. PMID: 31196127
Immune checkpoint markers in gastroenteropancreatic neuroendocrine neoplasia. Bösch F, Brüwer K, Altendorf-Hofmann A, Auernhammer CJ, Spitzweg C, Westphalen CB, Boeck S, Schubert-Fritschle G, Werner J, Heinemann V, Kirchner T, Angele M, Knösel T. Endocr Relat Cancer. 2019 Mar 1;26(3):293-301. doi: 10.1530/ERC-18-0494. PMID: 30608901

Neuroendocrine tumors of the small intestine causing a desmoplastic reaction of the mesentery are a more aggressive cohort. Bösch F, Bruewer K, D'Anastasi M, Ilhan H, Knoesel T, Pratschke S, Thomas M, Rentsch M, Guba M, Werner J, Angele MK. Surgery. 2018 Nov;164(5):1093-1099. doi: 10.1016/j.surg.2018.06.026. Epub 2018 Jul 31. PMID: 30076029
The role of GSK3 and its reversal with GSK3 antagonism in everolimus resistance. Aristizabal Prada ET, Spöttl G, Maurer J, Lauseker M, Koziolek EJ, Schrader J, Grossman A, Pacak K, Beuschlein F, Auernhammer CJ, Nölting S. Endocr Relat Cancer. 2018 Oct;25(10):893-908. doi: 10.1530/ERC-18-0159. Epub 2018 Jun 12. PMID: 29895527
Neuroendokrine Neoplasien im deutschen NET-Register [Neuroendocrine Neoplasia within the German NET Registry]. Im Namen aller Teilnehmer/innen am Deutschen NET-Registers; Authors; Kollaboratoren:. Z Gastroenterol. 2018 Oct;56(10):1237-1246. German. doi: 10.1055/a-0661-6099. Epub 2018 Oct 10. PMID: 30304748
Identification and characterization of myocardial metastases in neuroendocrine tumor patients using 68Ga-DOTATATE PET-CT. Kunz WG, Eschbach RS, Stahl R, Kazmierczak PM, Bartenstein P, Rominger A, Auernhammer CJ, Spitzweg C, Ricke J, Cyran CC. Cancer Imaging. 2018 Sep 20;18(1):34. doi: 10.1186/s40644-018-0168-2. PMID: 30236163
Surgical treatment of pNET - Experience of a "high-volume" center. Bösch F, Hofmann K, Coenen M, Pratschke S, Thomas M, Knösel T, Bruns CJ, Guba M, Werner J, Angele MK. Surg Oncol. 2018 Sep;27(3):409-414. doi: 10.1016/j.suronc.2018.05.027. Epub 2018 May 29. PMID: 30217295
Oligometastasierung bei neuroendokrinen Tumoren – Ausmaß der Chirurgie [Oligometastases of neuroendocrine tumors-extent of surgery]. Bösch F, Werner J, Angele MK, Guba MO. Chirurg. 2018 Jul;89(7):516-522. German. doi: 10.1007/s00104-018-0644-z. PMID: 29876615
Supportive therapy in gastroenteropancreatic neuroendocrine tumors: Often forgotten but important. Jin XF, Spampatti MP, Spitzweg C, Auernhammer CJ. Rev Endocr Metab Disord. 2018 Jun;19(2):145-158. doi: 10.1007/s11154-018-9443-6. PMID: 29464446
S2k-Leitlinie Neuroendokrine Tumore [Practice guideline neuroendocrine tumors - AWMF-Reg. 021-27]. Deutsche Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS); Netzwerk Neuroendokrine Tumoren (NeT) e.V. (Patientenvertretung); Bundesorganisation Selbsthilfe NeuroEndokrine Tumoren e.V. (NET-sgh) (Patientenvertretung); Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie e.V. (DGHO), und Arbeitsgemeinschaft Internistische Onkologie (AIO) der Deutschen Krebsgesellschaft e.V; Deutsche Gesellschaft für Allgemein- und Viszeralchirurgie e.V. (DGAV); Deutsche Gesellschaft für Chirurgie (DGCH); Deutsche Gesellschaft für Endoskopie und Bildgebende Verfahren (DGEBV); Deutsche Gesellschaft für Nuklearmedizin e.V. (DGNM); Deutsche Gesellschaft für Innere Medizin (DGIM); Deutsche Gesellschaft für Endokrinologie (DGE); Deutsche Gesellschaft für Palliativmedizin e.V. (DGP); Deutsche Röntgengesellschaft e.V. (DRG); Deutsche Gesellschaft für Pathologie e.V./Bundesverband Deutscher Pathologen (DGP/BDP); Deutsche Gesellschaft für interventionelle Radiologie (DGiR); Authors; Collaborators:. Z Gastroenterol. 2018 Jun;56(6):583-681. German. doi: 10.1055/a-0604-2924. Epub 2018 Jun 11. PMID: 29890561
Advanced neuroendocrine tumours of the small intestine and pancreas: clinical developments, controversies, and future strategies. Auernhammer CJ, Spitzweg C, Angele MK, Boeck S, Grossman A, Nölting S, Ilhan H, Knösel T, Mayerle J, Reincke M, Bartenstein P. Lancet Diabetes Endocrinol. 2018 May;6(5):404-415. doi: 10.1016/S2213-8587(17)30401-1. Epub 2017 Dec 8. PMID: 29229497
Tropomyosin receptor kinase: a novel target in screened neuroendocrine tumors. Aristizabal Prada ET, Heinzle V, Knösel T, Nölting S, Spöttl G, Maurer J, Spitzweg C, Angele M, Schmidt N, Beuschlein F, Stalla GK, Blaser R, Kuhn KA, Auernhammer CJ. Endocr Relat Cancer. 2018 May;25(5):547-560. doi: 10.1530/ERC-17-0201. Epub 2018 Mar 21. PMID: 29563190
GSK3α/β: A Novel Therapeutic Target for Neuroendocrine Tumors. Aristizabal Prada ET, Weis C, Orth M, Lauseker M, Spöttl G, Maurer J, Grabowski P, Grossman A, Auernhammer CJ, Nölting S. Neuroendocrinology. 2018;106(4):335-351. doi: 10.1159/000481887. Epub 2017 Oct 2. PMID: 28968593
The Novel Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) Alone and in Dual-Targeting Approaches Demonstrates Antitumoral Efficacy in Neuroendocrine Tumors in vitro. Aristizabal Prada ET, Nölting S, Spoettl G, Maurer J, Auernhammer CJ. Neuroendocrinology. 2018;106(1):58-73. doi: 10.1159/000463386. Epub 2017 Feb 23. PMID: 28226315
The HDM2 (MDM2) Inhibitor NVP-CGM097 Inhibits Tumor Cell Proliferation and Shows Additive Effects with 5-Fluorouracil on the p53-p21-Rb-E2F1 Cascade in the p53wild type Neuroendocrine Tumor Cell Line GOT1. Reuther C, Heinzle V, Nölting S, Herterich S, Hahner S, Halilovic E, Jeay S, Wuerthner JU, Aristizabal Prada ET, Spöttl G, Maurer J, Auernhammer CJ. Neuroendocrinology. 2018;106(1):1-19. doi: 10.1159/000453369. Epub 2016 Nov 21. PMID: 27871087
Targeted therapy of gastroenteropancreatic neuroendocrine tumours: preclinical strategies and future targets. Aristizabal Prada ET, Auernhammer CJ. Endocr Connect. 2018 Jan;7(1):R1-R25. doi: 10.1530/EC-17-0286. Epub 2017 Nov 16. PMID: 29146887

The selective PI3Kα inhibitor BYL719 as a novel therapeutic option for neuroendocrine tumors: Results from multiple cell line models. Nölting S, Rentsch J, Freitag H, Detjen K, Briest F, Möbs M, Weissmann V, Siegmund B, Auernhammer CJ, Aristizabal Prada ET, Lauseker M, Grossman A, Exner S, Fischer C, Grötzinger C, Schrader J, Grabowski P; GERMAN NET-Z study group. PLoS One. 2017 Aug 11;12(8):e0182852. doi: 10.1371/journal.pone.0182852. PMID: 28800359
Pre-therapeutic factors for predicting survival after radioembolization: a single-center experience in 389 patients. Paprottka KJ, Schoeppe F, Ingrisch M, Rübenthaler J, Sommer NN, De Toni E, Ilhan H, Zacherl M, Todica A, Paprottka PM. Eur J Nucl Med Mol Imaging. 2017 Jul;44(7):1185-1193. doi: 10.1007/s00259-017-3646-z. Epub 2017 Feb 14. PMID: 28197686
The MTH1 inhibitor TH588 demonstrates anti-tumoral effects alone and in combination with everolimus, 5-FU and gamma-irradiation in neuroendocrine tumor cells. Aristizabal Prada ET, Orth M, Nölting S, Spöttl G, Maurer J, Auernhammer C. PLoS One. 2017 May 25;12(5):e0178375. doi: 10.1371/journal.pone.0178375. PMID: 28542590
The Impact of Somatostatin Receptor-Directed PET/CT on the Management of Patients with Neuroendocrine Tumor: A Systematic Review and Meta-Analysis. Barrio M, Czernin J, Fanti S, Ambrosini V, Binse I, Du L, Eiber M, Herrmann K, Fendler WP. J Nucl Med. 2017 May;58(5):756-761. doi: 10.2967/jnumed.116.185587. Epub 2017 Jan 12. PMID: 28082438
Efficacy of peptide receptor radionuclide therapy with 177Lu-octreotate in metastatic pulmonary neuroendocrine tumors: a dual-centre analysis. Sabet A, Haug AR, Eiden C, Auernhammer CJ, Simon B, Bartenstein P, Biersack HJ, Ezziddin S. Am J Nucl Med Mol Imaging. 2017 Apr 15;7(2):74-83. PMID: 28533939
The added value of 68Ga-DOTA-TATE-PET to contrast-enhanced CT for primary site detection in CUP of neuroendocrine origin. Kazmierczak PM, Rominger A, Wenter V, Spitzweg C, Auernhammer C, Angele MK, Rist C, Cyran CC. Eur Radiol. 2017 Apr;27(4):1676-1684. doi: 10.1007/s00330-016-4475-3. Epub 2016 Jul 19. PMID: 27436022
Neuroendokrine Neoplasien des Magens : Was ist neu? [Neuroendocrine neoplasia of the stomach : What is new?]. Knösel T, Reiter C, Schubert-Fritschle G, Altendorf-Hofmann A, Kirchner T. Pathologe. 2017 Mar;38(2):98-104. German. doi: 10.1007/s00292-017-0269-x. PMID: 28188377
Survival prediction in patients undergoing radionuclide therapy based on intratumoral somatostatin-receptor heterogeneity. Werner RA, Lapa C, Ilhan H, Higuchi T, Buck AK, Lehner S, Bartenstein P, Bengel F, Schatka I, Muegge DO, Papp L, Zsótér N, Große-Ophoff T, Essler M, Bundschuh RA. Oncotarget. 2017 Jan 24;8(4):7039-7049. doi: 10.18632/oncotarget.12402. PMID: 27705948

Nephroprotective effects of enalapril after [177Lu]-DOTATATE therapy using serial renal scintigraphies in a murine model of radiation-induced nephropathy. Ilhan H, Wang H, Gildehaus FJ, Wängler C, Herrler T, Todica A, Schlichtiger J, Cumming P, Bartenstein P, Hacker M, Haug AR. EJNMMI Res. 2016 Dec;6(1):64. doi: 10.1186/s13550-016-0219-2. Epub 2016 Aug 11. PMID: 27515447
Characterization of pancreatic glucagon-producing tumors and pituitary gland tumors in transgenic mice overexpressing MYCN in hGFAP-positive cells. Fielitz K, Althoff K, De Preter K, Nonnekens J, Ohli J, Elges S, Hartmann W, Klöppel G, Knösel T, Schulte M, Klein-Hitpass L, Beisser D, Reis H, Eyking A, Cario E, Schulte JH, Schramm A, Schüller U. Oncotarget. 2016 Nov 15;7(46):74415-74426. doi: 10.18632/oncotarget.12766. PMID: 27769070
RSUME is implicated in tumorigenesis and metastasis of pancreatic neuroendocrine tumors. Wu Y, Tedesco L, Lucia K, Schlitter AM, Garcia JM, Esposito I, Auernhammer CJ, Theodoropoulou M, Arzt E, Renner U, Stalla GK. Oncotarget. 2016 Sep 6;7(36):57878-57893. doi: 10.18632/oncotarget.11081. PMID: 27506944
Effectiveness and side-effects of peptide receptor radionuclide therapy for neuroendocrine neoplasms in Germany: A multi-institutional registry study with prospective follow-up. Hörsch D, Ezziddin S, Haug A, Gratz KF, Dunkelmann S, Miederer M, Schreckenberger M, Krause BJ, Bengel FM, Bartenstein P, Biersack HJ, Pöpperl G, Baum RP. Eur J Cancer. 2016 May;58:41-51. doi: 10.1016/j.ejca.2016.01.009. Epub 2016 Mar 2. PMID: 26943056
Cabozantinib and Tivantinib, but Not INC280, Induce Antiproliferative and Antimigratory Effects in Human Neuroendocrine Tumor Cells in vitro: Evidence for 'Off-Target' Effects Not Mediated by c-Met Inhibition. Reuther C, Heinzle V, Spampatti M, Vlotides G, de Toni E, Spöttl G, Maurer J, Nölting S, Göke B, Auernhammer CJ. Neuroendocrinology. 2016;103(3-4):383-401. doi: 10.1159/000439431. Epub 2015 Aug 25. PMID: 26338447

Additive Anti-Tumor Effects of Lovastatin and Everolimus In Vitro through Simultaneous Inhibition of Signaling Pathways. Nölting S, Maurer J, Spöttl G, Aristizabal Prada ET, Reuther C, Young K, Korbonits M, Göke B, Grossman A, Auernhammer CJ. PLoS One. 2015 Dec 4;10(12):e0143830. doi: 10.1371/journal.pone.0143830. PMID: 26636335
Predictive Value of 99mTc-MAA SPECT for 90Y-Labeled Resin Microsphere Distribution in Radioembolization of Primary and Secondary Hepatic Tumors. Ilhan H, Goritschan A, Paprottka P, Jakobs TF, Fendler WP, Todica A, Bartenstein P, Hacker M, Haug AR. J Nucl Med. 2015 Nov;56(11):1654-60. doi: 10.2967/jnumed.115.162685. Epub 2015 Aug 27. PMID: 26315830
Intestinal neuroendocrine cells and goblet cells are mediators of IL-17A-amplified epithelial IL-17C production in human inflammatory bowel disease. Friedrich M, Diegelmann J, Schauber J, Auernhammer CJ, Brand S. Mucosal Immunol. 2015 Jul;8(4):943-58. doi: 10.1038/mi.2014.124. Epub 2014 Dec 10. PMID: 25492478
Towards new response criteria in neuroendocrine tumors: which changes in MRI parameters are associated with longer progression-free survival after radioembolization of liver metastases? Ceelen F, Theisen D, de Albéniz XG, Auernhammer CJ, Haug AR, D'Anastasi M, Paprottka PM, Rist C, Reiser MF, Sommer WH. J Magn Reson Imaging. 2015 Feb;41(2):361-8. doi: 10.1002/jmri.24569. Epub 2014 Jan 21. PMID: 24446275
Impact of (68)Ga-DOTATATE PET/CT on the surgical management of primary neuroendocrine tumors of the pancreas or ileum. Ilhan H, Fendler WP, Cyran CC, Spitzweg C, Auernhammer CJ, Gildehaus FJ, Bartenstein P, Angele MK, Haug AR. Ann Surg Oncol. 2015 Jan;22(1):164-71. doi: 10.1245/s10434-014-3981-2. Epub 2014 Sep 5. PMID: 25190113

Anticancer effects of metformin on neuroendocrine tumor cells in vitro. Vlotides G, Tanyeri A, Spampatti M, Zitzmann K, Chourdakis M, Spttl C, Maurer J, Nölting S, Göke B, Auernhammer CJ. Hormones (Athens). 2014 Oct-Dec;13(4):498-508. doi: 10.14310/horm.2002.1517. Epub 2014 Nov 5. PMID: 25402373
Aspirin inhibits cell viability and mTOR downstream signaling in gastroenteropancreatic and bronchopulmonary neuroendocrine tumor cells. Spampatti M, Vlotides G, Spöttl G, Maurer J, Göke B, Auernhammer CJ. World J Gastroenterol. 2014 Aug 7;20(29):10038-49. doi: 10.3748/wjg.v20.i29.10038. PMID: 25110431
Diagnostic accuracy of dynamic gadoxetic-acid-enhanced MRI and PET/CT compared in patients with liver metastases from neuroendocrine neoplasms. Armbruster M, Zech CJ, Sourbron S, Ceelen F, Auernhammer CJ, Rist C, Haug A, Singnurkar A, Reiser MF, Sommer WH. J Magn Reson Imaging. 2014 Aug;40(2):457-66. doi: 10.1002/jmri.24363. Epub 2013 Dec 18. PMID: 24347148
Neuroendokrine Tumoren des Verdauungstrakts - Daten des deutschen NET-Registers [Neuroendocrine tumours of the GI tract--data from the German NET Registry]. Begum N, Maasberg S, Plöckinger U, Anlauf M, Rinke A, Pöpperl G, Lehnert H, Izbicki JR, Krausch M, Vashist YK, Raffel A, Bürk CG, Hoffmann J, Goretzki P, Pape UF; Weitere Vertreter des deutschen NET-Registers. Zentralbl Chir. 2014 Jun;139(3):276-83. German. doi: 10.1055/s-0032-1315199. Epub 2012 Oct 5. PMID: 23042103
Neuroendokrine Neoplasien des distalen Jejunums und Ileums [Neuroendocrine neoplasms of the distal jejunum and ileum]. Anlauf M, Sipos B, Boeck I, Baldus SE, Heikaus S, Krausch M, Knoefel WT, Begum N, Goretzki P, Schott M, Auernhammer CJ, Cremer B, Rinke A, Ezziddin S, Fottner C, Pöpperl G, Lahner H, Hörsch D, Gabbert HE, Komminoth P, Perren A, Klöppel G, Wiedenmann B, Pavel M, Pape U. Pathologe. 2014 May;35(3):283-93; quiz 294. German. doi: 10.1007/s00292-013-1888-5. PMID: 24671468
Neuroendocrine tumor recurrence: diagnosis with 68Ga-DOTATATE PET/CT. Haug AR, Cindea-Drimus R, Auernhammer CJ, Reincke M, Beuschlein F, Wängler B, Uebleis C, Schmidt GP, Spitzweg C, Bartenstein P, Hacker M. Radiology. 2014 Feb;270(2):517-25. doi: 10.1148/radiol.13122501. Epub 2013 Oct 28. PMID: 24056402
Evaluation of neuroendocrine liver metastases: a comparison of dynamic contrast-enhanced magnetic resonance imaging and positron emission tomography/computed tomography. Armbruster M, Sourbron S, Haug A, Zech CJ, Ingrisch M, Auernhammer CJ, Nikolaou K, Paprottka PM, Rist C, Reiser MF, Sommer WH. Invest Radiol. 2014 Jan;49(1):7-14. doi: 10.1097/RLI.0b013e3182a4eb4a. PMID: 24002080
Treatment with octreotide in patients with well-differentiated neuroendocrine tumors of the ileum: prognostic stratification with Ga-68-DOTA-TATE positron emission tomography. Koch W, Auernhammer CJ, Geisler J, Spitzweg C, Cyran CC, Ilhan H, Bartenstein P, Haug AR. Mol Imaging. 2014;13:1-10. PMID: 24824963

Potent antitumor activity of the novel HSP90 inhibitors AUY922 and HSP990 in neuroendocrine carcinoid cells. Zitzmann K, Ailer G, Vlotides G, Spoettl G, Maurer J, Göke B, Beuschlein F, Auernhammer CJ. Int J Oncol. 2013 Dec;43(6):1824-32. doi: 10.3892/ijo.2013.2130. Epub 2013 Oct 4. PMID: 24100469
Defining predictors for long progression-free survival after radioembolisation of hepatic metastases of neuroendocrine origin. Sommer WH, Ceelen F, García-Albéniz X, Paprottka PM, Auernhammer CJ, Armbruster M, Nikolaou K, Haug AR, Reiser MF, Theisen D. Eur Radiol. 2013 Nov;23(11):3094-103. doi: 10.1007/s00330-013-2925-8. Epub 2013 Jun 28. PMID: 23807569
The novel somatostatin receptor 2/dopamine type 2 receptor chimeric compound BIM-23A758 decreases the viability of human GOT1 midgut carcinoid cells. Zitzmann K, Andersen S, Vlotides G, Spöttl G, Zhang S, Datta R, Culler M, Göke B, Auernhammer CJ. Neuroendocrinology. 2013;98(2):128-36. doi: 10.1159/000353784. Epub 2013 Jul 31. PMID: 23797089
Comparison of abdominal MRI with diffusion-weighted imaging to 68Ga-DOTATATE PET/CT in detection of neuroendocrine tumors of the pancreas. Schmid-Tannwald C, Schmid-Tannwald CM, Morelli JN, Neumann R, Haug AR, Jansen N, Nikolaou K, Schramm N, Reiser MF, Rist C. Eur J Nucl Med Mol Imaging. 2013 Jun;40(6):897-907. doi: 10.1007/s00259-013-2371-5. Epub 2013 Mar 5. PMID: 23460395
Peptide receptor radionuclide therapy for neuroendocrine tumors in Germany: first results of a multi-institutional cancer registry. Hörsch D, Ezziddin S, Haug A, Gratz KF, Dunkelmann S, Krause BJ, Schümichen C, Bengel FM, Knapp WH, Bartenstein P, Biersack HJ, Plöckinger U, Schwartz-Fuchs S, Baum RP. Recent Results Cancer Res. 2013;194:457-65. doi: 10.1007/978-3-642-27994-2_25. PMID: 22918775

The role of 68Ga-DOTATATE PET/CT in suspected neuroendocrine tumors. Haug AR, Cindea-Drimus R, Auernhammer CJ, Reincke M, Wängler B, Uebleis C, Schmidt GP, Göke B, Bartenstein P, Hacker M. J Nucl Med. 2012 Nov;53(11):1686-92. doi: 10.2967/jnumed.111.101675. Epub 2012 Sep 14. PMID: 22984220
Fluid-fluid level in hepatic metastases: a characteristic sign of metastases of neuroendocrine origin. Sommer WH, Zech CJ, Bamberg F, Auernhammer CJ, Helck A, Paprottka PM, Notohamiprodjo M, Reiser MF, Herrmann KA. Eur J Radiol. 2012 Sep;81(9):2127-32. doi: 10.1016/j.ejrad.2011.09.012. Epub 2011 Oct 5. PMID: 21978774
Combined quantification of liver perfusion and function with dynamic gadoxetic acid-enhanced MR imaging. Sourbron S, Sommer WH, Reiser MF, Zech CJ. Radiology. 2012 Jun;263(3):874-83. doi: 10.1148/radiol.12110337. Erratum in: Radiology. 2012 Sep;264(3):920. PMID: 22623698
Perifosine-mediated Akt inhibition in neuroendocrine tumor cells: role of specific Akt isoforms. Zitzmann K, Vlotides G, Brand S, Lahm H, Spöttl G, Göke B, Auernhammer CJ. Endocr Relat Cancer. 2012 May 24;19(3):423-34. doi: 10.1530/ERC-12-0074. PMID: 22499437
Radioembolization of symptomatic, unresectable neuroendocrine hepatic metastases using yttrium-90 microspheres. Paprottka PM, Hoffmann RT, Haug A, Sommer WH, Raessler F, Trumm CG, Schmidt GP, Ashoori N, Reiser MF, Jakobs TF. Cardiovasc Intervent Radiol. 2012 Apr;35(2):334-42. doi: 10.1007/s00270-011-0248-1. Epub 2011 Aug 17. PMID: 21847708
Contrast agents as a biological marker in magnetic resonance imaging of the liver: conventional and new approaches. Sommer WH, Sourbron S, Huppertz A, Ingrisch M, Reiser MF, Zech CJ. Abdom Imaging. 2012 Apr;37(2):164-79. doi: 10.1007/s00261-011-9734-9. PMID: 21516381
Gastrointestinale gemischte adenoneuroendokrine Karzinome. Versuch einer Ordnung des Gemischten [Gastrointestinal mixed adenoneuroendocrine carcinomas. An attempt at classification of mixed cancers]. Reu S, Neumann J, Kirchner T. Pathologe. 2012 Feb;33(1):31-8. German. doi: 10.1007/s00292-011-1552-x. PMID: 22293787
Neuroendokrine Tumoren des gastroenteropankreatischen Systems: Nuklearmedizinische Diagnostik und Therapie [Gastroenteropancreatic neuroendocrine tumors: diagnosis and therapy in nuclear medicine]. Haug AR, Bartenstein P. Internist (Berl). 2012 Feb;53(2):161-6. German. doi: 10.1007/s00108-011-2918-0. PMID: 22231696
Medikamentöse Therapie bei metastasierten neuroendokrinen Tumoren des gastroenteropankreatischen Systems [Medicinal therapy of metastasized neuroendocrine tumors of the gastroenteropancreatic system]. Auernhammer CJ, Spitzweg C, Heinemann V, Göke B. Internist (Berl). 2012 Feb 2. German. doi: 10.1007/s00108-011-2919-z. Epub ahead of print. PMID: 22294240

Arterial therapies of non-colorectal cancer metastases to the liver (from chemoembolization to radioembolization). Hoffmann RT, Paprottka P, Jakobs TF, Trumm CG, Reiser MF. Abdom Imaging. 2011 Dec;36(6):671-6. doi: 10.1007/s00261-011-9753-6. PMID: 21584635
Treatment with octreotide does not reduce tumor uptake of (68)Ga-DOTATATE as measured by PET/CT in patients with neuroendocrine tumors. Haug AR, Rominger A, Mustafa M, Auernhammer C, Göke B, Schmidt GP, Wängler B, Cumming P, Bartenstein P, Hacker M. J Nucl Med. 2011 Nov;52(11):1679-83. doi: 10.2967/jnumed.111.089276. Epub 2011 Oct 5. PMID: 21976529
Therapeutic strategies for advanced neuroendocrine carcinomas of jejunum/ileum and pancreatic origin. Auernhammer CJ, Göke B. Gut. 2011 Jul;60(7):1009-21. doi: 10.1136/gut.2009.204453. Epub 2011 Mar 4. PMID: 21378384
The novel Raf inhibitor Raf265 decreases Bcl-2 levels and confers TRAIL-sensitivity to neuroendocrine tumour cells. Zitzmann K, de Toni E, von Rüden J, Brand S, Göke B, Laubender RP, Auernhammer CJ. Endocr Relat Cancer. 2011 Mar 21;18(2):277-85. doi: 10.1530/ERC-10-0108. PMID: 21317202

Progrediente Dyspnoe bei Karzinoidsyndrom [Progressive dyspnoea in two patients with carcinoid syndrome]. Nölting S, Nicolaus M, Behr J, Baumgartner R, Mete H, Boekstegers P, Herrmann K, Theisen D, Lehrke M, Göke B, Schirra J, Auernhammer CJ. Internist (Berl). 2010 Nov;51(11):1439-45. German. doi: 10.1007/s00108-010-2649-7. PMID: 20628718
Compensatory activation of Akt in response to mTOR and Raf inhibitors - a rationale for dual-targeted therapy approaches in neuroendocrine tumor disease. Zitzmann K, Rüden Jv, Brand S, Göke B, Lichtl J, Spöttl G, Auernhammer CJ. Cancer Lett. 2010 Sep 1;295(1):100-9. doi: 10.1016/j.canlet.2010.02.018. Epub 2010 Mar 30. PMID: 20356670
68Ga-DOTATATE PET/CT for the early prediction of response to somatostatin receptor-mediated radionuclide therapy in patients with well-differentiated neuroendocrine tumors. Haug AR, Auernhammer CJ, Wängler B, Schmidt GP, Uebleis C, Göke B, Cumming P, Bartenstein P, Tiling R, Hacker M. J Nucl Med. 2010 Sep;51(9):1349-56. doi: 10.2967/jnumed.110.075002. Epub 2010 Aug 18. PMID: 20720050
Quantifizierung der Somatostatinrezeptorexpression neuroendokriner Tumoren mit der (68)Ga-DOTATATE-PET/CT [Quantification of immunohistochemical expression of somatostatin receptors in neuroendocrine tumors using 68Ga-DOTATATE PET/CT]. Haug AR, Assmann G, Rist C, Tiling R, Schmidt GP, Bartenstein P, Hacker M. Radiologe. 2010 Apr;50(4):349-54. German. doi: 10.1007/s00117-009-1972-2. PMID: 20333502
Radiofrequency ablation after selective internal radiation therapy with Yttrium90 microspheres in metastatic liver disease-Is it feasible? Hoffmann RT, Jakobs TF, Kubisch CH, Stemmler HJ, Trumm C, Tatsch K, Helmberger TK, Reiser MF. Eur J Radiol. 2010 Apr;74(1):199-205. doi: 10.1016/j.ejrad.2009.02.001. Epub 2009 Mar 9. PMID: 19269763
Anti insulin-like growth factor I receptor immunoliposomes: a single formulation combining two anticancer treatments with enhanced therapeutic efficiency. Hantel C, Lewrick F, Schneider S, Zwermann O, Perren A, Reincke M, Süss R, Beuschlein F. J Clin Endocrinol Metab. 2010 Feb;95(2):943-52. doi: 10.1210/jc.2009-1980. Epub 2009 Dec 1. PMID: 19952224

Lebermetastasierung bei neuroendokrinen Karzinomen des gastro-entero-pankreatischen Systems--Therapiestrategien [Liver metastases from neuroendocrine tumours of the gastroenteropancreatic system--therapeutic strategies]. Auernhammer CJ, Jauch KW, Hoffmann JN. Zentralbl Chir. 2009 Sep;134(5):410-7. German. doi: 10.1055/s-0029-1224607. Epub 2009 Sep 15. PMID: 19757340
Intraindividual comparison of 68Ga-DOTA-TATE and 18F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours. Haug A, Auernhammer CJ, Wängler B, Tiling R, Schmidt G, Göke B, Bartenstein P, Pöpperl G. Eur J Nucl Med Mol Imaging. 2009 May;36(5):765-70. doi: 10.1007/s00259-008-1030-8. Epub 2009 Jan 10. PMID: 19137293
Gastrointestinale Onkologie - Therapieupdate 2008 / 2009 [Gastrointestinal oncology - therapy update 2008 / 2009]. Ebert MP, Auernhammer C, Caca K, Eckel F, Fischbach W, Geissler M, Göke B, Greten T, Kubicka S, Lutz MP, Möhler M, Opitz O, Pavel M, Porschen R, Reinacher-Schick A, Schmiegel W, Seufferlein T, Wiedenmann B, Schmid RM. Z Gastroenterol. 2009 Mar;47(3):296-306. German. doi: 10.1055/s-2008-1027989. Epub 2009 Mar 6. PMID: 19267319
Morphologisches Erscheinungsbild neuroendokriner Tumoren des Dünndarms im MR-Enteroklysma [Characteristic imaging features of carcinoid tumors of the small bowel in MR enteroclysis]. Schmid-Tannwald C, Zech CJ, Panteleon A, Sommer WH, Auernhammer C, Herrmann KA. Radiologe. 2009 Mar;49(3):242-5, 248-51. German. doi: 10.1007/s00117-008-1783-x. PMID: 19198795

Therapieresponse von Lebertumoren nach selektiver interner Radiotherapie [Therapy response of liver tumors after selective internal radiation therapy]. Jakobs TF, Hoffmann RT, Tatsch K, Trumm C, Reiser MF. Radiologe. 2008 Sep;48(9):839-49. German. doi: 10.1007/s00117-008-1730-x. PMID: 18766324
Consensus guidelines for the management of patients with digestive neuroendocrine tumors--well-differentiated jejunal-ileal tumor/carcinoma. Eriksson B, Klöppel G, Krenning E, Ahlman H, Plöckinger U, Wiedenmann B, Arnold R, Auernhammer C, Körner M, Rindi G, Wildi S; Frascati Consensus Conference participants. Neuroendocrinology. 2008;87(1):8-19. doi: 10.1159/000111034. Epub 2007 Dec 12. PMID: 18097129

SOCS1 silencing enhances antitumor activity of type I IFNs by regulating apoptosis in neuroendocrine tumor cells. Zitzmann K, Brand S, De Toni EN, Baehs S, Göke B, Meinecke J, Spöttl G, Meyer HH, Auernhammer CJ. Cancer Res. 2007 May 15;67(10):5025-32. doi: 10.1158/0008-5472.CAN-06-2575. PMID: 17510435
The novel mTOR inhibitor RAD001 (everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells. Zitzmann K, De Toni EN, Brand S, Göke B, Meinecke J, Spöttl G, Meyer HH, Auernhammer CJ. Neuroendocrinology. 2007;85(1):54-60. doi: 10.1159/000100057. Epub 2007 Feb 19. Erratum in: Neuroendocrinology. 2009 Oct;90(3):250. Dosage error in article text. PMID: 17310129
Medical treatment of gastrinomas. Auernhammer CJ, Göke B. Wien Klin Wochenschr. 2007;119(19-20):609-15. doi: 10.1007/s00508-007-0877-1. PMID: 17985097

Publikationen GEPNET-KUM

Wissenschaftliche Publikationen aus dem GEPNET-KUM

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

2014

2013

2012

2011

2010

2009

2008

2007

2006

Publikationen GEPNET-KUM

Wissenschaftliche Publikationen aus dem GEPNET-KUM

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

2014

2013

2012

2011

2010

2009

2008

2007

2006

50 Jahre Campus Großhadern - Tag der offenen Tür